In this free webinar, discover the value of in-trial interview data in drug development. Attendees will learn how in-trial qualitative data are used by regulators and health technology assessment (HTA) bodies. Attendees can also participate in a pre-survey about their experience with in-trial data, with results shared during the webinar. The featured speakers will provide practical examples showcasing the real-world application of interview data.
TORONTO, Aug. 16, 2024 /PRNewswire/ -- Regulatory health authorities now recognize the significance and value of in-trial qualitative interviews in gaining greater insight into and understanding of the patient experience. These interviews provide supplementary data that can greatly enhance clinical trial design, interpretation of findings and product value for payers while addressing the unmet needs of patients. However, there is still a need for greater understanding regarding:
- The utilization of qualitative evidence in drug development
- How this evidence is valorized during evaluation by regulators and HTA bodies
- Its implications for reimbursement decision-makers
In this webinar, the expert speakers will explore the added value of in-trial interview data in drug development and its pivotal role as a driver in decision-making for regulatory and HTA decisions. The discussion will draw from a range of identified case studies and findings from multiple data sources, including:
- Food and Drug Administration (FDA) and European Medicines Agency (EMA) medicinal product labels: Reviews of in-trial interview data from 2017 to 2023
- HTA Reports: Examination of products that include qualitative research in their drug development
- Guidance Documents: Recent regulatory, HTA and other clinical guidance related to qualitative research
Attendees will be invited to participate in a pre-survey about their experience using in-trial data in regulatory and HTA submissions, the results of which will be presented during the webinar with key points addressed for knowledge-sharing.
Register for this webinar today to gain insights into how qualitative evidence enhances clinical trials, influences regulatory evaluations and affects health technology assessments and reimbursement decisions.
Join experts from Evidera, part of the PPD clinical research business of Thermo Fisher Scientific, Carla Dias-Barbosa, MSc, Senior Research Leader & In-trial Research Lead, Patient-Centered Research; Miriam Kimel, PhD, Senior Research Scientist, Patient-Centered Research; Karen Bailey, PhD, Research Scientist, Patient-Centered Research; and Paulina Rolska-Wójcik, PhD, Director, Value & Access Consulting, for the live webinar on Wednesday, September 11, 2024, at 10am EDT (3pm BST/UK).
For more information, or to register for this event, visit Beyond Numbers: The Value of In-Trial Interview Data for Regulatory and Health Technology Assessment (HTA) Decision-Making.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article